Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00670306 · ClinicalTrials.gov registry record · Phase 3
Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)
A Phase 3 study of Benign Prostatic Hypertrophy, sponsored by AEterna Zentaris.
- Completed
- Registry status
- Phase 3
- Development phase
- 528
- Enrollment target
- 20
- Study locations
NCT00670306: Completed Phase 3 study of Benign Prostatic Hypertrophy, sponsored by AEterna Zentaris.
NCT00670306 is a Phase 3 study of Benign Prostatic Hypertrophy that has completed, run by AEterna Zentaris. The registered enrollment target is 528 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (32% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00670306, a Phase 3 study of Benign Prostatic Hypertrophy, has completed, sponsored by AEterna Zentaris.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 528 participants
- Enrollment target
- 20
- Study locations
Study Summary
Benign Prostatic Hyperplasia (BPH) is the most common hyperplastic disease occuring in human males over the age of 50 which increases in prevalence with age and 40% of males reported moderate or severe urinary symptoms of prostatism by the age of 50 to 80. The purpose of this study is to collect safety and efficacy data for this dosage regimen of cetrorelix pamoate. For this study, study medication (Cetrorelix pamoate) is administered by injection in the buttocks (Intramuscular).
Primary Outcome
International Prostate Symptom Score (IPSS) Patient Questionnaire assessing 7 items (incomplete voiding, frequency, intermittency, urgency, weak stream, hesitancy, nocturia) on a scale from 0 (best) to 5 (worst); total range: 0 - 35 points; absolute change from baseline to Week 26
Conditions Studied
Interventions
- DRUG Cetrorelix Pamoate
Study Locations (20)
California
- South Orange County Medical Research Center - Laguna Hills
- California Professionnal Research - Newport Beach
- Northern California Research - Sacramento
- San Diego Uro Research - San Diego
- Medical Center for Clinical Research - San Diego
- West Coast Clinical Research - Tarzana
Florida
- South Florida Medical Research - Aventura
- Tampa Bay Medical Research - Clearwater
- University Urologists - Lake Worth
- Specialists in Urology - Naples
- Winter Park Urology - Orlando
- Florida Urology Specialists - Sarasota
Alabama
- Urology Centers of Alabama - Homewood
- Medical Affiliated Research Center, Inc. - Huntsville
Connecticut
- Connecticut Clincal Research Center, LLC - Middlebury
- Urological Associates of Bridgeport - Trumbull
Colorado
- Genitourinary Surgical Consultants - Denver
Georgia
- Mount Vernon Clinical Research, LLC - Sandy Springs
Idaho
- North Idaho Urology - Coeur d'Alene
Indiana
- Northeast Indiana Research, LLC - Fort Wayne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 528 participants |
| Start Date | 2008-03 |
| Est. Completion | 2009-08 |
| Phase | Phase 3 |
What the finished NCT00670306 record still lists
NCT00670306 is an interventional study that assigns participants to a tested intervention. The registered 528 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (32% lower).
The record links to 1 condition, with Benign Prostatic Hypertrophy appearing as the primary indexed condition, and to 1 intervention - of which Cetrorelix Pamoate is the first listed.
NCT00670306 names 20 study sites across 8 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT00670306 about?
NCT00670306 is a clinical study titled "Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)". Benign Prostatic Hyperplasia (BPH) is the most common hyperplastic disease occuring in human males over the age of 50 which increases in prevalence with age and 40% of males reported moderate or severe urinary symptoms of prostatism by the age of 50 to 80. The purpose of this study is to collect saf...
What is the current status of trial NCT00670306?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 528 participants. The study started on 2008-03. Estimated completion is 2009-08.
What conditions does trial NCT00670306 study?
This clinical trial studies the following conditions: Benign Prostatic Hypertrophy.
What interventions are being tested in trial NCT00670306?
The interventions under investigation include: Cetrorelix Pamoate (DRUG).
Who is sponsoring clinical trial NCT00670306?
This trial is sponsored by AEterna Zentaris, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00670306 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Benign Prostatic Hypertrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00670306's enrollment target sits among peer trials
528 711th of 2000 higher than 1,286 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05373017 · 528 participants · NA
Delirium and Neuropsychological Recovery Among Emergency General Surgery Survivors
- NCT05634252 · 528 participants · Phase 3
Undergraduate Skin Cancer Prevention Trial
- NCT06383273 · 528 participants · Phase 3
A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)
- NCT06470243 · 528 participants · Phase 3
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia